Please try another search
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
David C. Hodgson | 67 | 2022 | Independent Director |
Pablo Gerardo Legorreta | 59 | 1996 | Founder, Chairman of the Board & CEO |
Henry A. Fernandez | 66 | 2020 | Lead Independent Director |
Gregory Norden | 66 | 2020 | Independent Director |
Ted W. Love | 65 | 2020 | Independent Director |
Catherine M. Engelbert | 59 | 2020 | Independent Director |
Errol B. De Souza | 71 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review